Geoff Martha, CEO of Medtronic, Declares a Surge in Durable Mid-Single Digit Revenue Growth, Backed by Strong Fundamentals and Game-Changing Innovations

Medtronic plc announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key Highlights Revenue of $8...

November 22, 2023 | Wednesday | Company results
Emergent CEO, Haywood Miller, Highlights Financial Growth and Opioid Crisis Response Efforts as Company Pursues Resilient Future.

Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023. The selected financia...

November 09, 2023 | Thursday | Company results
Gilead's CEO, Daniel O'Day, Steers the Ship to Two Years of Unwavering Growth in Virology and Oncology

Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion Oncology Sales In...

November 08, 2023 | Wednesday | Company results
Pfizer's Dr. Albert Bourla Applauds Q3 2023 Triumphs and Bold Expansion Plans, Paving the Way for a Transformative Future in Oncology and Beyond

Third-Quarter 2023 Revenues of $13.2 Billion Expected Decline in Paxlovid and Comirnaty(1) Revenues Drove 41% Operational Decrease in Third-Quarter 20...

November 02, 2023 | Thursday | Company results
Revvity's CEO Prahlad Singh Navigates Stormy Q3 Waters, Pledges Stronger Future Amid Market Uncertainty

Revenue of $671 million; (6)% reported growth; (7)% organic growth; 1% non-COVID organic growth GAAP EPS of $0.08; Adjusted EPS from continuing oper...

October 31, 2023 | Tuesday | Company results
QIAGEN CEO Thierry Bernard Hails Remarkable Quarter, Sees Bright Future on the Horizon

Q3 2023: Net sales of $476 million (-5% at actual rates, -6% at constant exchange rates, CER); diluted EPS of $0.34 and adjusted diluted EPS of $0.50 // Ne...

October 31, 2023 | Tuesday | Company results
Bio-Rad CEO, Norman Schwartz, Discusses Q3 Results and Adjusts 2023 Outlook Amid Biopharma Challenges

  Third-quarter 2023 total net sales were $632.1 million, a decrease of 7.1 percent compared to $680.8 million reported for the third quarter of 20...

October 30, 2023 | Monday | Company results
Marc Casper's Leadership Propels Thermo Fisher to Strong Q3 Performance Amid Market Challenges

Third Quarter 2023 Highlights Third quarter revenue was $10.57 billion, 1% lower versus the same quarter last year. Core organic revenue growth was 1%. ...

October 26, 2023 | Thursday | Company results
Merck CEO Belén Garijo Expresses Confidence in Resilient Growth Model for 2024

Transitional year 2023 managed well so far thanks to resilient business model Medium-term growth targets confirmed Merck expects continued growth also ...

October 25, 2023 | Wednesday | Company results
Novartis Reports Stellar Quarter with Double-Digit Sales Growth, CEO Vas Narasimhan Confident in Strong Mid-Term Outlook

Transformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is on continuing o...

October 24, 2023 | Tuesday | Company results
Roche CEO Thomas Schinecker Reflects on Impressive 2023 Results, Aims for a Bright Future Beyond COVID-19

Group sales grow by 1%1 at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarter Excluding COVID-...

October 20, 2023 | Friday | Company results
Sartorius CEO Joachim Kreuzburg Foresees Gradual Recovery in 2023, Eyes Strong Growth in 2024 and Beyond

Sales revenue in constant currencies down 16.4 percent, excluding Covid-19-related business down slightly above 10 percent; underlying EBITDA marg...

October 20, 2023 | Friday | Company results
Novo Nordisk raises sales and operating profit outlook for 2023

In the first nine months of 2023, Novo Nordisk’s sales increased by 33% and operating profit increased by 37% both at CER. Profit and loss (CE...

October 16, 2023 | Monday | News
Avantor CEO Michael Stubblefield Commends Utilization of Avantor Business System to Navigate Tough Market Trends, Expresses Confidence in Long-Term Growth

  "While market trends during the quarter, especially in biopharma, were more challenging than anticipated, we leveraged the Avantor Business System ...

August 29, 2023 | Tuesday | Company results

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2023 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in